SYNGENE Syngene International Q4 FY26 results (Jan–Mar 2026) and concall
Syngene International reported a muted 3% YoY top-line growth for FY26, primarily due to the significant impact of Librela destocking, which is expected to continue affecting FY27. Despite this, Q4 showed strong sequential growth of 13%, and the company maintained a robust financial position with healthy free cash flow and a strong net cash balance. Strategic investments in advanced modalities and an extended partnership with Bristol-Myers Squibb are expected to position Syngene for stronger growth from FY28, following a transitional FY27.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 1.8%, net profit down 19.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 891 | 944 | 1,018 | 875 | 911 +2% | 917 −3% | 1,037 +2% |
| EBITDA | 245 | 284 | 344 | 206 | 200 −19% | 209 −26% | 303 −12% |
| Net profit | 106 | 131 | 183 | 87 | 67 −37% | 15 −89% | 148 −19% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
